Mark Cornfeld

1.2k total citations
33 papers, 838 citations indexed

About

Mark Cornfeld is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Mark Cornfeld has authored 33 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Mark Cornfeld's work include Cancer Immunotherapy and Biomarkers (7 papers), Multiple Myeloma Research and Treatments (4 papers) and Viral-associated cancers and disorders (4 papers). Mark Cornfeld is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Multiple Myeloma Research and Treatments (4 papers) and Viral-associated cancers and disorders (4 papers). Mark Cornfeld collaborates with scholars based in United States, France and Italy. Mark Cornfeld's co-authors include Xiang Qin, Ming Qi, Peter M. Voorhees, Johann S. de Bono, G. R. Hudes, Razelle Kurzrock, Karim Fizazi, Sagar Lonial, Éric Voog and Axel Heidenreich and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Mark Cornfeld

31 papers receiving 829 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Cornfeld United States	11	497	294	157	151	127	33	838
Charlotte Lemech Australia	16	389 0.8×	262 0.9×	146 0.9×	114 0.8×	108 0.9×	63	695
R. Angelo de Claro United States	15	424 0.9×	202 0.7×	201 1.3×	62 0.4×	154 1.2×	40	815
Sheng Yang China	16	406 0.8×	149 0.5×	192 1.2×	196 1.3×	63 0.5×	105	781
S. Vukelja United States	10	707 1.4×	179 0.6×	80 0.5×	82 0.5×	109 0.9×	30	911
Prakash Kharel United States	6	739 1.5×	249 0.8×	342 2.2×	205 1.4×	102 0.8×	13	1.0k
Suthee Rapisuwon United States	11	683 1.4×	329 1.1×	246 1.6×	158 1.0×	43 0.3×	30	997
Gordon Moody United States	11	303 0.6×	281 1.0×	139 0.9×	209 1.4×	135 1.1×	24	836
Nicola Calvani Italy	16	382 0.8×	325 1.1×	296 1.9×	139 0.9×	157 1.2×	46	911
Melanie J. McCoy Australia	16	323 0.6×	218 0.7×	324 2.1×	164 1.1×	63 0.5×	28	1.0k
Sheeja T. Pullarkat United States	13	508 1.0×	234 0.8×	179 1.1×	122 0.8×	116 0.9×	43	980

Countries citing papers authored by Mark Cornfeld

Since Specialization

Citations

This map shows the geographic impact of Mark Cornfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Cornfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Cornfeld more than expected).

Fields of papers citing papers by Mark Cornfeld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Cornfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Cornfeld. The network helps show where Mark Cornfeld may publish in the future.

Co-authorship network of co-authors of Mark Cornfeld

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Cornfeld. A scholar is included among the top collaborators of Mark Cornfeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Cornfeld. Mark Cornfeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grignani, Giovanni, Piotr Rutkowski, Célèste Lebbé, et al.. (2025). Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201). Journal for ImmunoTherapy of Cancer. 13(8). e012478–e012478. 2 indexed citations

Schenker, Michael, Jacques Médioni, Sławomir Mańdziuk, et al.. (2024). A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). ESMO Open. 9(3). 102387–102387. 6 indexed citations

Berton, Dominique, Patricia Pautier, Domenica Lorusso, et al.. (2024). Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study. Gynecologic Oncology. 186. 191–198. 2 indexed citations

Grignani, Giovanni, Piotr Rutkowski, Célèste Lebbé, et al.. (2023). 1146P Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC). Annals of Oncology. 34. S686–S686. 10 indexed citations

Rao, Sheela, Jaume Capdevila, Duncan C. Gilbert, et al.. (2020). LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy. Annals of Oncology. 31. S1170–S1171. 19 indexed citations

Diab, Adi, Cara Haymaker, Marc Uemura, et al.. (2017). A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. Annals of Oncology. 28. v421–v421. 11 indexed citations

Tolcher, Anthony W., Amita Patnaik, Kyriakos P. Papadopoulos, et al.. (2014). Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemotherapy and Pharmacology. 75(1). 183–189. 129 indexed citations

Hudes, Gary R., Scott T. Tagawa, Young E. Whang, et al.. (2012). A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Investigational New Drugs. 31(3). 669–676. 54 indexed citations

Kurzrock, Razelle, Peter M. Voorhees, Corey Casper, et al.. (2011). Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,. Blood. 118(21). 3959–3959. 3 indexed citations

10.

Fizazi, Karim, Johann S. de Bono, Aude Fléchon, et al.. (2011). Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer. 48(1). 85–93. 158 indexed citations

11.

Schipperus, Martin R., et al.. (2010). Hepcidin Levels and Erythropoietin Alfa Resistance In Patients with Chemotherapy Induced Anemia (CIA). Blood. 116(21). 3216–3216.

12.

Vermeulen, Jessica, et al.. (2010). A randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328, an anti-IL-6) in patients with multicentric Castleman's disease.. Journal of Clinical Oncology. 28(15_suppl). TPS186–TPS186. 2 indexed citations

13.

Schipperus, Martin R., et al.. (2009). CNTO328 (Anti-IL-6 mAb) Treatment Is Associated with An Increase in Hemoglobin (Hb) and Decrease in Hepcidin Levels in Renal Cell Carcinoma (RCC).. Blood. 114(22). 4045–4045. 9 indexed citations

14.

Rhee, Frits van, Luis Fayad, Peter M. Voorhees, et al.. (2008). CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study.. Blood. 112(11). 1008–1008. 6 indexed citations

15.

Kurzrock, Razelle, Luis Fayad, Peter M. Voorhees, et al.. (2008). A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.. Blood. 112(11). 1009–1009. 4 indexed citations

16.

Schnoll, Robert A., Hao Wang, Suzanne M. Miller, et al.. (2005). Change in Worksite Smoking Behavior Following Cancer Risk Feedback: A Pilot Study. American Journal of Health Behavior. 29(3). 215–227. 9 indexed citations

17.

Schnoll, Robert A., Pamela Bradley, Suzanne M. Miller, et al.. (2003). Psychological issues related to the use of spiral CT for lung cancer early detection. Lung Cancer. 39(3). 315–325. 35 indexed citations

18.

Marsh, John C., Paul J. Catalano, Jie Huang, et al.. (2002). Eastern Cooperative Oncology Group Phase II Trial (E4296) of Oral 5-Fluorouracil and Eniluracil as a 28-Day Regimen in Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 2(1). 43–50. 10 indexed citations

19.

Cornfeld, Mark, Suzanne M. Miller, Eric A. Ross, & Dona Schneider. (2001). Accuracy of cancer-risk assessment in primary care practice.. PubMed. 16(4). 193–8. 9 indexed citations

20.

Cornfeld, Mark, et al.. (2001). Feasibility of Assessing Quality in Medical Oncology Practices. Cancer Practice. 9(5). 231–235. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact